Crosland Andrew, Cortes-Sanchez Pablo Manuel, Sudunagunta Siddharth, Bouvard Jonathan, Bode Elizabeth, Culshaw Geoff, Dukes-McEwan Joanna
Department of Small Animal Clinical Science, School of Veterinary Science, University of Liverpool, Cardiology Service, Small Animal Teaching Hospital, Chester High Road, Neston CH64 7TE, UK.
The Royal (Dick) School of Veterinary Studies, Easter Bush Campus, The University of Edinburgh, Cardiology Service, Hospital for Small Animals, Midlothian EH25 9RG, UK.
Vet Sci. 2024 Nov 25;11(12):594. doi: 10.3390/vetsci11120594.
The present study aimed to evaluate the effects of chronic pimobendan monotherapy on cardiac size in dogs with stage B2 myxomatous mitral valve disease (MMVD). Data from 31 dogs diagnosed with MMVD and cardiomegaly (LA/Ao ≥ 1.6 and LVIDdn ≥ 1.7) were included. The intervention group were dogs treated with pimobendan (n = 24). Dogs not receiving any cardiac medication were controls (n = 7). Echocardiographic changes in left atrial and left ventricular dimensions were compared over time. There was significant group × time interaction for LVIDdN ( = 0.011) between diagnosis and initial follow-up (median 3-6 months). There was a significant reduction in LVIDdN over time in the pimobendan group ( = 0.038) but not in the control group ( = 0.216). There was no significant group × time interaction for LA/Ao, and there was no effect of group ( = 0.561), but LA/Ao in both groups decreased over time ( = 0.01). Restraint is advised when prescribing pimobendan based on the detection of a heart murmur where echocardiographic staging is an option. Some stage B2 dogs that received pimobendan no longer met the echocardiographic classification criteria for stage B2 MMVD and could have been misclassified as stage B1 and had their medication inappropriately withdrawn. We suggest these dogs are referred to as reverse remodelled stage B2.
本研究旨在评估慢性匹莫苯丹单一疗法对患有B2期黏液瘤性二尖瓣疾病（MMVD）犬心脏大小的影响。纳入了31只被诊断为MMVD且有心脏扩大（左心房/主动脉≥1.6且左心室舒张末期内径≥1.7）的犬的数据。干预组为接受匹莫苯丹治疗的犬（n = 24）。未接受任何心脏药物治疗的犬作为对照组（n = 7）。比较了随时间变化的左心房和左心室尺寸的超声心动图变化。在诊断和初始随访（中位时间3 - 6个月）之间，左心室舒张末期内径（LVIDdN）存在显著的组×时间交互作用（P = 0.011）。匹莫苯丹组的LVIDdN随时间有显著降低（P = 0.038），而对照组则无显著变化（P = 0.216）。左心房/主动脉不存在显著的组×时间交互作用，且组间无效应（P = 0.561），但两组的左心房/主动脉均随时间下降（P = 0.01）。当根据心杂音检测开具匹莫苯丹处方且可选择超声心动图分期时，建议谨慎使用。一些接受匹莫苯丹治疗的B2期犬不再符合B2期MMVD的超声心动图分类标准，可能被误分类为B1期并被不恰当地停用药物。我们建议将这些犬称为逆向重构的B2期。
